Home › Funds › Propel Bio Management, LLC › ARTV
Propel Bio Management, LLC position in ARTV
ARTIVA BIOTHERAPEUTICS INC · Health Care
Propel Bio Management, LLC reported holding 696,436 shares of ARTV (ARTIVA BIOTHERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$5.0M, representing 2.63% of its reported portfolio and ranking #13 among its reported holdings. Propel Bio Management, LLC has disclosed ARTV holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Propel Bio Management, LLC's ARTV position evolved
Propel Bio Management, LLC first disclosed a stake in ARTV in Q1 2026 at 146,369 shares (US$950K). The position peaked in Q2 2026 at 696,436 shares, worth US$6.8M. Across 3 filings, Propel Bio Management, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 696,436 shares valued at US$5.0M. Notable position changes include a 376% increase in Q2 2026 (shares fell 27% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 146.37K | $949.82K | New |
| Q2 2026 | 696.44K | $6.76M | Add |
| Q3 2026 | 696.44K | $4.96M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ARTV and 13F data
ARTV (ARTIVA BIOTHERAPEUTICS INC) is a Health Care company. 70 other funds we track also report a position in ARTV — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$174.2M), Blue Owl Capital Holdings LP (US$63.8M), 5AM Venture Management, LLC (US$22.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ARTV
- RA CAPITAL MANAGEMENT, L.P. 17.96M sh · $174.17M · Q2 2026
- Blue Owl Capital Holdings LP 4.13M sh · $63.84M · Q3 2026
- 5AM Venture Management, LLC 2.35M sh · $22.83M · Q2 2026
- Venrock Adviser, LLC 2.04M sh · $19.82M · Q2 2026
- Caligan Partners LP 1.74M sh · $16.84M · Q2 2026
- Sanofi 672.78K sh · $11.24M · Q3 2026
- Samsara BioCapital, LLC 954.86K sh · $9.26M · Q2 2026
- ACUTA CAPITAL PARTNERS, LLC 260.42K sh · $2.53M · Q2 2026
- Revelation Capital Management, LLC 299.31K sh · $2.13M · Q3 2026
- KVP Capital Advisors, LP 200.00K sh · $1.94M · Q2 2026
- CRCM LP 25.39K sh · $423.95K · Q3 2026
- Velan Capital Investment Management LP 25.00K sh · $242.50K · Q2 2026
More on Propel Bio Management, LLC
FAQ
How long has Propel Bio Management, LLC held ARTV?
Propel Bio Management, LLC has disclosed ARTV holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Propel Bio Management, LLC's current position in ARTV?
As of Q3 2026, Propel Bio Management, LLC holds 696.44K shares of ARTV (ARTIVA BIOTHERAPEUTICS INC), valued at $4.96M, representing 2.63% of its reported portfolio and ranking #13.
Has Propel Bio Management, LLC been buying or selling ARTV?
In the latest 13F filing (Q3 2026), Propel Bio Management, LLC held unchanged its position in ARTV. The position peaked in Q2 2026 at 696.44K shares.
Which other funds hold ARTV?
Other major institutional holders of ARTV include RA CAPITAL MANAGEMENT, L.P., Blue Owl Capital Holdings LP, 5AM Venture Management, LLC, among 70 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.